+

WO1996000087A3 - Kit for pretargeting and novel pretargeting conjugates - Google Patents

Kit for pretargeting and novel pretargeting conjugates Download PDF

Info

Publication number
WO1996000087A3
WO1996000087A3 PCT/EP1995/002425 EP9502425W WO9600087A3 WO 1996000087 A3 WO1996000087 A3 WO 1996000087A3 EP 9502425 W EP9502425 W EP 9502425W WO 9600087 A3 WO9600087 A3 WO 9600087A3
Authority
WO
WIPO (PCT)
Prior art keywords
pretargeting
conjugates
kit
targeting
novel
Prior art date
Application number
PCT/EP1995/002425
Other languages
French (fr)
Other versions
WO1996000087A2 (en
Inventor
Ebo Sybren Bos
Franciscus Michael Kaspersen
Original Assignee
Akzo Nobel Nv
Ebo Sybren Bos
Franciscus Michael Kaspersen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Ebo Sybren Bos, Franciscus Michael Kaspersen filed Critical Akzo Nobel Nv
Priority to AU28871/95A priority Critical patent/AU2887195A/en
Publication of WO1996000087A2 publication Critical patent/WO1996000087A2/en
Publication of WO1996000087A3 publication Critical patent/WO1996000087A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to a method of pretargeting therapeutic or diagnostic compounds to target cells in the body and a kit for such a method. The targeting is preferably through a specific antibody. The binding between the preinjected targeting moiety and the effector moiety is established by a zinc finger and its cognate nucleotide sequence, conjugated to the targeting or effector moiety. Also part of the invention are conjugates of zinc fingers and therapeutic or diagnostic compounds.
PCT/EP1995/002425 1994-06-24 1995-06-22 Kit for pretargeting and novel pretargeting conjugates WO1996000087A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU28871/95A AU2887195A (en) 1994-06-24 1995-06-22 Kit for pretargeting and novel pretargeting conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94201826 1994-06-24
EP94201826.8 1994-06-24

Publications (2)

Publication Number Publication Date
WO1996000087A2 WO1996000087A2 (en) 1996-01-04
WO1996000087A3 true WO1996000087A3 (en) 1996-03-07

Family

ID=8216990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002425 WO1996000087A2 (en) 1994-06-24 1995-06-22 Kit for pretargeting and novel pretargeting conjugates

Country Status (2)

Country Link
AU (1) AU2887195A (en)
WO (1) WO1996000087A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20020082979A (en) * 2001-04-24 2002-11-01 이명철 vagina contract pressure gauge
MX353608B (en) 2012-02-24 2018-01-19 Alteogen Inc Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008220A1 (en) * 1989-12-01 1991-06-13 Gunnar Houen A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines
WO1992011365A1 (en) * 1990-12-21 1992-07-09 The Rockefeller University Liver enriched transcription factor
WO1993017707A1 (en) * 1992-03-04 1993-09-16 Akzo N.V. In vivo binding pair pretargeting
EP0650735A2 (en) * 1993-07-09 1995-05-03 Akzo Nobel N.V. Kit and method for pretargeting

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008220A1 (en) * 1989-12-01 1991-06-13 Gunnar Houen A method for the stepwise, controlled synthesis of chemical species, particularly peptides, coupled products obtained by the method and the use of these coupled products, e.g. as vaccines
WO1992011365A1 (en) * 1990-12-21 1992-07-09 The Rockefeller University Liver enriched transcription factor
WO1993017707A1 (en) * 1992-03-04 1993-09-16 Akzo N.V. In vivo binding pair pretargeting
EP0650735A2 (en) * 1993-07-09 1995-05-03 Akzo Nobel N.V. Kit and method for pretargeting

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; *
HSIEH J. C. ET AL.: "RECEPTOR MEDIATED GENOMIC ACTION OF THE 1,25 (OH)2D3 HORMONE: EXPRESSION OF THE HUMAN VITAMIN D RECEPTOR IN E. COLI.", J. STEROID BIOCHEM. MOL. BIOL., vol. 53, no. 1, pages 583 - 594 *
LUO Z. ET AL.: "A PEPTIDE C-TERMINAL TO THE SECOND ZN FINGER OF HUMAN VITAMIN D RECEPTOR IS ABLE TO SPECIFY NUCLEAR LOCALIZATION.", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 223, no. 2, pages 384 - 387 *

Also Published As

Publication number Publication date
WO1996000087A2 (en) 1996-01-04
AU2887195A (en) 1996-01-19

Similar Documents

Publication Publication Date Title
CA2015060A1 (en) Novel antibody delivery system for biological response modifiers
CA2249320A1 (en) Glycosylated humanized b-cell specific antibodies
KR970700771A (en) Non-viral vector
WO2000056774A8 (en) Methods of using bioelastomers
WO2000076550A3 (en) Carrier-drug conjugate
AU1250483A (en) Conjugate of enzyme and antibody
CA2134239A1 (en) Pretargeting methods and compounds
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
CA2239167A1 (en) Aldolase catalytic antibody
WO2002082041A3 (en) Production and use of novel peptide-based agents for use with bi-specific antibodies
AU2639395A (en) Covalent microparticle-drug conjugates for biological targeting
WO2000005265A3 (en) Anti-crr2 antibodies and methods of use therefor
CA2215933A1 (en) Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
WO1999041273A3 (en) Pna and dna conjugates and methods for preparation thereof
WO1998023646A3 (en) Binding agents specific for IGA receptor
WO2002078638A3 (en) Morpholino imaging and therapy
CA2067244A1 (en) Monoclonal antibody specific for iga receptor
WO1999040214A8 (en) Nucleic acid delivery vehicles
WO1996000087A3 (en) Kit for pretargeting and novel pretargeting conjugates
IE64781B1 (en) Immunoglobulin conjugates
WO2003033653A3 (en) Affinity enhancement agents
EP0453097A3 (en) Zusammensetzung enthaltend zumindest zwei verschiedene Antikörper oder deren Fragmente
GB8927230D0 (en) Reagents
EP1023906A4 (en) Potentiator for antibody against lymphoid tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA FI JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA FI JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载